Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,727,283.05 in Stock

Key Points

• Executive Sale: Alnylam Pharmaceuticals' EVP Jeffrey Poulton sold 3,821 shares for $1,727,283.05, reducing his holdings by 6.60% to 54,052 shares valued at over $24 million.
• Stock Performance: The company's shares recently traded down to $456.35, and have a significant market capitalization of $59.82 billion, with a 1-year trading range from $205.87 to $484.21.
• Quarterly Earnings: Alnylam reported $0.32 EPS for the quarter, exceeding expectations, alongside a revenue of $773.69 million, marking a 17.3% increase year-over-year.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Jeffrey Poulton sold 3,821 shares of the company's stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the sale, the executive vice president directly owned 54,052 shares of the company's stock, valued at $24,434,206.60. The trade was a 6.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded down $4.64 during midday trading on Friday, hitting $456.35. 969,084 shares of the company's stock traded hands, compared to its average volume of 982,632. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $484.21. The stock has a market capitalization of $59.82 billion, a price-to-earnings ratio of -184.76 and a beta of 0.36. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a fifty day moving average of $439.02 and a 200 day moving average of $337.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The firm had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business's revenue for the quarter was up 17.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

ALNY has been the subject of several analyst reports. Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals in a report on Monday, July 21st. They issued a "buy" rating and a $385.00 target price for the company. Wolfe Research upgraded Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research note on Monday, August 4th. Wall Street Zen downgraded Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. JPMorgan Chase & Co. upped their price target on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Alnylam Pharmaceuticals in a research note on Saturday, September 27th. Twenty-four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $439.58.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. Brighton Jones LLC bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $243,000. Wealth Enhancement Advisory Services LLC lifted its position in Alnylam Pharmaceuticals by 94.7% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 12,566 shares of the biopharmaceutical company's stock worth $2,957,000 after buying an additional 6,112 shares during the last quarter. Merit Financial Group LLC lifted its position in Alnylam Pharmaceuticals by 113.0% in the first quarter. Merit Financial Group LLC now owns 5,314 shares of the biopharmaceutical company's stock worth $1,435,000 after buying an additional 2,819 shares during the last quarter. Whipplewood Advisors LLC lifted its position in Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 71 shares during the last quarter. Finally, TB Alternative Assets Ltd. bought a new stake in Alnylam Pharmaceuticals in the first quarter worth $2,476,000. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.